Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in pMMR Locally Advanced Rectal Adenocarcinoma
NCT07104604Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in rectal adenocarcinoma, sponsored by Affiliated Cancer Hospital of Shantou University Medical College. Started Oct 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07104604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104604.